News: Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

117.25GBp
11:37am EDT
Price Change (% chg)

0.25p (+0.21%)
Prev Close
117.00p
Open
119.75p
Day's High
119.75p
Day's Low
117.00p
Volume
576,741
Avg. Vol
449,648
52-wk High
171.50p
52-wk Low
100.47p

Search Stocks
Select another date:

Thu, Sep 4 2014

BRIEF-Vectura says partner Novartis signs marketing deal with Pfizer UK

* Announcement of commercial arrangement with Pfizer UK to promote Ultibro Breezhaler and Seebri Breezhaler in United Kingdom Source text for Eikon: Further company coverage:

BRIEF-Vectura performance from April to date in line with board's expectations

* Product pipeline is progressing in line with board's expectations

BRIEF-Vectura says in US collaboration agreement for VR506 asthma therapy

* Announces a further US collaboration agreement with a leading international pharmaceutical company for VR506 asthma therapy

UPDATE 2-Vectura revenue jumps on royalty push, sees more growth

* Shares rise as much as 3.5 pct (Adds CEO and analyst comments; updates share movement)

Vectura revenue rises 20 pct on higher royalty payments

May 21 - Drug developer Vectura Group Plc reported a 20 percent rise in full-year revenue as it benefited from higher royalty payments for drugs it has licensed.

BRIEF-Vectura Group revenue rises 20 pct

* FY revenue rises 20 percent to 36.5 million stg (2012/13: 30.5 million stg)

Select another date:

Press Releases

Search Stocks